ARID3B

Across TCGA pan-cancer cohorts, ARID3B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ARID3B data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARID3B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARID3B expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where ARID3B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.804	1.000	.013	6	view →
LSCC	OS	Median	II,III,IV	0.957	0.785	.033	3	view →
LUAD	DFS	Tertile	All	1.000	0.436	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ARID3B–HNSC (DFS)

Open the HNSC breakdown →